



Novel Insights on Cancer Stem Cells

Guest Editor:

Dr. Veronica Veschi

Department of Surgical and
Oncological Sciences, Università
degli Studi di Palermo, Palermo,
Italy

Deadline for manuscript
submissions:

closed (30 June 2024)

Message from the Guest Editor

Dear Colleagues,

Cancer stem cells (CSCs) or cancer-initiating cells are an aggressive subpopulation present in a range of 1/1000 to 5–10/100 in the tumor bulk of different cancer types, including thyroid cancer and colorectal cancer, respectively. It has been demonstrated that this subpopulation is endowed with high metastatic potential and characterized by high expression levels of efflux pumps, self-renewal capacity and therapy resistance. Standard treatments fail to effectively impair tumor growth because of the persistence of this small subpopulation. The development of innovative therapeutic approaches that specifically target CSCs is urgently needed.

In this Special Issue entitled “Novel Insights on Cancer Stem Cells”, we encourage the submission of original research papers and reviews regarding the most recent advances focused on unravelling innovative therapeutic strategies targeting CSCs or mechanisms regulating CSC maintenance, epigenetic reprogramming and resistance to therapy.

Dr. Veronica Veschi
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)